Article

Correlating basal gene expression across chemical sensitivity data to screen for novel synergistic interactors of HDAC inhibitors in pancreatic carcinoma

2022-10-13

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is considered as one of the most aggressive and lethal malignancies. Development of chemoresistance in PDAC is one of the key contributors for the poor survival outcomes of PDAC patients and the major reason for urgent development of novel pharmacological approaches for effective treatment of PDAC. Systematically tailored combination therapy holds the promise for advancing t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4a832de4-3572-5244-9911-1459abd84f0f
DOI: 10.1101/2022.10.10.511584

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Correlating basal gene expression across chemical sensitivity data to screen for novel synergistic interactors of HDAC inhibitors in pancreatic carcinomaDOI 10.1101/2022.10.10.511584Read

Histone Deacetylase Inhibitors Restore Cancer Cell Sensitivity towards T Lymphocytes Mediated Cytotoxicity in Pancreatic CancerSemantic proximity Read

Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer CellsSemantic proximity Read

Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read

Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer.Semantic proximity Read

Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumorsSemantic proximity Read

HDAC-Linked “Proliferative” miRNA Expression Pattern in Pancreatic Neuroendocrine TumorsSemantic proximity Read

Sonic hedgehog inhibitor suppresses carcinoma associated fibroblasts to prime Gemcitabine/Nab-Paclitaxel and anti-CTLA4 immunotherapy as sequential first-line combination therapy in a Phase 1b/2 study in PDAC: NUMANTIA trialSemantic proximity Read

Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cellsSemantic proximity Read

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancerSemantic proximity Read

Repurposing proteasome inhibitors in the treatment of esophageal squamous cell cancerSemantic proximity Read

Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transitionSemantic proximity Read

Deciphering molecular mechanisms of synergistic growth reduction in kinase inhibitor combinationsSemantic proximity Read